



Press Release

JenaValve Names Michael J. Dormer as Chairman of the Board

DELAWARE, USA and MUNICH, Germany, April 6th, 2009 — JenaValve™ Technology, Inc., a medical device company specialized in developing minimally-invasive heart valve replacement systems, today announced the appointment of Mr. Michael J. Dormer as Chairman of the Board of Directors, effective March 1st, 2009.

Mr. Dormer draws from a wealth of experience spanning an outstanding 30-year career, most prominently with Johnson & Johnson, where he served as Worldwide Chairman, Medical Devices and Executive Committee Member. He also served on the Executive Committee of The Advanced Medical Technology Association where he was a strong proponent of the code of business conduct.

"I am extremely proud that Mike has joined us as Chairman," said CEO Helmut J. Straubinger. "His extensive medical industry experience and success in acquisitions and strategic alliances will contribute immeasurably to our company."

"I look forward to working closely with the board and JenaValve management as it executes on its mission to offer significant minimally-invasive heart valve replacement advancements," said Michael J. Dormer.

Dormer joins existing board members Helmut J. Straubinger, Dr. Dr. Markus Ferrari, Dr. Regina Hodits and Dr. Olivier Litzka.

About JenaValve Technology

JenaValve Technology is a medical device company specialized in developing minimally-invasive heart valve replacement systems. The company is currently developing two aortic valve replacement systems for transapical and transfemoral approaches.

JenaValve systems feature several differentiators: an auto positioning mechanism used to place the implant safely and accurately, the possibility of repositioning during the entire procedure, an unrivaled fixation technique for attaching the aortic valve on the stent and a unique clip-based anchoring mechanism within the aorta. These features enable JenaValve to build AVR systems that offer maximum safety for patients and physicians alike.

The company's products will be targeted at high-risk patients unsuitable for open heart surgery. JenaValve Technology GmbH is headquartered in Munich, Germany; its holding, JenaValve Technology, Inc., is based in Delaware, USA.

Further information is available at www.jenavalve.de.

JenaValve and JenaClip are trademarks of JenaValve Technology GmbH. The JenaValve™ products are protected by pending and granted patent, design and utility model rights.

Disclaimer

All information contained in this document derives from plausible reliable sources, which, however, have not been independently examined. There is no warranty, confirmation or guarantee and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this document or its contents. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. International investors acknowledge risks in connection with political and economic uncertainties in foreign countries as well as currency risks. Persons who are in possession of this document are requested to obtain information concerning possible legal limitations and to observe them accordingly.

A photograph of Mr. Dormer is available upon request.

Press contacts:

Lucy Turpin Communications GmbH
Brigitte Wenske, PR & MarCom Manager
jenavalve@lucyturpin.com
Tel. +49 (0)89 417761-42